Exome-based genomic markers could improve prediction of checkpoint inhibitor efficacy independently of tumor type

HIGHLIGHTS

• who: Lorraine Dalens and collaborators from the Department of Medical Oncology, Georges Leclerc Cancer Center-UNICANCER, UFR des Sciences de Santu00e9, University of Burgundy-Franche-Comtu00e9, Dijon, France have published the Article: Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type, in the Journal: (JOURNAL)
• what: The aim of this study was to identify genomic biomarkers that predict response to immunotherapy and to generate a genomic prediction score for response to ICIs. The authors show here that a lower number of TCR clones and low Shannon entropy were associated . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.